Physician profile
Michael Shawn Machuzak
NPI 1851355085
$285,986.44
in general payments reported to CMS, 2019-2025
25 companies · $28K in 2025
The $28K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88K · 2020: $29K · 2021: $14K · 2022: $30K · 2023: $40K · 2024: $58K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $63K · Education: $48K · Travel and Lodging: $8,642 · Food and Beverage: $5,177 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $62,668.53 |
| Education | $48,222.50 |
| Travel and Lodging | $8,641.92 |
| Food and Beverage | $5,176.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $440.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $181,680.22 | 2019-2025 | Single Use Suction Valve (Sterile), Olympus, Eves Eus Ultrasound Bronchofibervideoscope |
| Ethicon INC. | $36,160.32 | 2019-2025 | Monarch, Monarch Platform |
| Medical Device Business Services, INC. | $22,271.67 | 2023-2024 | Monarch, Monarch Platform |
| Olympus America INC. | $17,659.48 | 2019-2024 | Eves Eus Ultrasound Bronchofibervideoscope, Spiration Valve System |
| Olympus Medical Systems Corporation | $7,150.00 | 2024 | |
| Serpex Medical INC | $6,624.79 | 2023-2025 | |
| Body Vision Medical INC. | $4,543.39 | 2023-2024 | Lungvision |
| Gyrus Acmi, INC. | $3,630.00 | 2020-2023 | |
| Ethicon Endo-Surgery INC. | $1,366.47 | 2023 | Neuwave |
| Olympus Corporation | $1,042.90 | 2023 | |
| Noah Medical Corporation | $649.50 | 2023-2025 | Galaxy |
| Boston Scientific Corporation | $645.73 | 2019-2024 | Exalt Model D, Acquire |
| Pulmonx Corporation | $486.18 | 2019-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Intuitive Surgical, INC. | $449.73 | 2019-2025 | Da Vinci Surgical System |
| Veran Medical Technologies, INC. | $440.00 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $350.00 | 2025 | |
| Auris Health, INC. | $226.72 | 2019 | |
| Getinge USA Sales, LLC | $158.89 | 2019 | |
| Ambu INC. | $117.62 | 2022 | |
| Covidien Lp | $113.55 | 2019 | |
| Philips North America LLC | $96.69 | 2024 | (Bi2) Igt Systems Undivided |
| Ethicon US, LLC | $80.78 | 2023 | Neuwave |
| Icu Medical INC | $15.81 | 2023 | |
| Genentech USA, INC. | $13.82 | 2021 | |
| Medtronic, INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Machuzak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.